2-Jul-2026
No headlines found.
GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs
Business Wire (Wed, 27-May 9:00 AM ET)
GoodRx Reports First Quarter 2026 Results
Business Wire (Wed, 6-May 4:05 PM ET)
GoodRx Expands Offerings to Now Include Ozempic Pill for Type 2 Diabetes Patients
Business Wire (Fri, 1-May 8:10 AM ET)
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call
Business Wire (Fri, 17-Apr 4:05 PM ET)
GoodRx Now Offers Access to Wegovy HD at $399 Per Month Self-Pay Price
Business Wire (Wed, 15-Apr 9:00 AM ET)
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Goodrx Holdings - Class A trades on the NASDAQ stock market under the symbol GDRX.
As of July 2, 2026, GDRX stock price declined to $3.05 with 1,346,431 million shares trading.
GDRX has a beta of 1.57, meaning it tends to be more sensitive to market movements. GDRX has a correlation of 0.07 to the broad based SPY ETF.
GDRX has a market cap of $1.03 billion. This is considered a Small Cap stock.
Last quarter Goodrx Holdings - Class A reported $194 million in Revenue and $.07 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.01.
In the last 3 years, GDRX traded as high as $9.37 and as low as $1.77.
The top ETF exchange traded funds that GDRX belongs to (by Net Assets): VTI, VB, VXF, VBR, SCHA.
GDRX has underperformed the market in the last year with a return of -39.7%, while SPY returned +21.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GDRX shares. However, GDRX has outperformed the market in the last 3 month and 2 week periods, returning +48.8% and +14.7%, while SPY returned +13.9% and -0.3%, respectively. This indicates GDRX has been having a stronger performance recently.
GDRX support price is $2.94 and resistance is $3.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GDRX shares will trade within this expected range on the day.